

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial

In the format provided by the
authors and unedited

Supplement to : **Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial**

Apperloo et.al.

Corresponding author:

H.J L Heerspink; Department Clinical Pharmacy and Pharmacology; University Medical Center Groningen; Hanzeplein 1; PO Box 30.001; 9700 RB; Groningen; The Netherlands
Tel: +31 50 361 7859; E-mail: h.j.lambers.heerspink@umcg.nl

Table of Contents:

Supplementary appendix 1: SMART contributing investigators

Supplementary appendix 1: SMART contributing investigators

Canada

University of Toronto

Kevin Yau MD

Vikas S. Sridhar MD

University of Calgary

Sandra M. Dumanski MD MSc

Germany

University of Erlangen

Dennis Kannenkeril M.D.

Merve Günes-Altan M.D.

Venera Bytyqi M.D

University of Wurzburg

K Lopau

V Sokalski

Netherlands

University of Groningen

David Smeijer MD

Bettine Haandrikman

ZiekenhuisGroep Twente Almelo

Annis Jalving MD

Jelle Beernink MD

Spain

Vall d'Hebron University Hospital Barcelona

Emma Pardo, MSc

Sheila Bermejo

University Clinical Hospital, INCLIVA Research Institute

Francesc Moncho Frances MD

Elena Giménez Civera MD

Bellvitge Hospital

Maria Quero, MD, PhD

Núria Montero, MD, PhD

Edoardo Melilli, MD, PhD

Hospital Ribera Polusa

Juan Carlos Primo MD

Raquel Vazquez

Amaia Santidrian